Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?

Table 2 Clinical characteristics

	Total N = 44
Mean of Patients’ Onset of Neuropathic Pain Diagnosis in Years (SD) [Range]	7.5 (8.1) [1.0-40.0]
Type of Neuropathic Pain (n, %)
Postherpetic Neuralgia (PHN)	8 (18.2%)
HIV-associated Neuropathy (HIV-AN)	16 (36.4%)
Painful Diabetic Peripheral Neuropathy (PDPN)	20 (45.5%)
Mean of Patient’s Rating of Pain (SD) [Range]	6.9 (1.7) [3.0-10.0]
Frequency of Opioid Medication ¹
Hydrocodone	5 (11.4%)
Oxycodone	1(2.3%)
Other²	9 (20.5%)
Frequency of Non-Opioid Medication ¹
Pregabalin	13 (29.6%)
Duloxetine	7 (15.9%)
Gabapentin	27 (61.4%)
Other³	24 (54.5%)
Frequency of Topical Medication ¹
QUTENZA^TM	11 (25.0%)
Lidocaine	3 (6.8%)
Other⁴	2 (4.6%)
Mean Patient Height, feet (SD) [Range]	5.5 (0.4) [4.5-6.2]
Mean Patient Weight, pounds (SD) [Range]	196.7 (45.9) [108.0-315.0]

¹These categories are not mutually exclusive.
²Other Opioid medications reported by participants included: Darvocet (n=1); MS Contin (n=1); Tramadol (n=6); Vicodin (n=1).
³Other Non-Opioid medications reported included: Advil (n=2); Aleve (n=1); Amitriptyline (n=3); Aspirin (n=2); Baclofen (n=1); Carbamalbpine (n=1); Celebrex (n=1); Cymbalta (n=1); Diclofenac (n=1); Glipizide (n=1); Motrin (n=1); Naproxen (n=2); Nortriptyline (n=1); Topamax (n=3); Tylenol (n=1); Tylenol Extra Strength (n=2).
⁴Other Topical medications reported by participants included: Amitriptyline 5%, Gabapentin 5%, Ketamine 8% (n=1); Zotrix 0.75 Cream (n=1).

ISSN: 1477-7525